Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for All Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 2 by Treatment Group for All Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for Baseline ZIKV Seropositive Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 2 by Treatment Group for Baseline ZIKV Seropositive Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for Baseline ZIKV Seronegative Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 2 by Treatment Group for Baseline ZIKV Seronegative Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for Baseline ZIKV Seropositive and DENV Seropositive Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 2 by Treatment Group for Baseline ZIKV Seropositive and DENV Seropositive Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for Baseline ZIKV Seropositive and DENV Seronegative Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 2 by Treatment Group for Baseline ZIKV Seropositive and DENV Seronegative Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for Baseline ZIKV Seronegative and DENV Seropositive Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 2 by Treatment Group for Baseline ZIKV Seronegative and DENV Seropositive Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for Baseline ZIKV Seronegative and DENV Seronegative Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Local Events Post Dose 2 by Treatment Group for Baseline ZIKV Seronegative and DENV Seronegative Participants
The following injection site reactogenicity events were measured: pain, tenderness, pruritus, ecchymosis, erythema, and induration. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 1 by Treatment Group for All Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 2 by Treatment Group for All Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 1 by Treatment Group for Baseline ZIKV Seropositive Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 2 by Treatment Group for Baseline ZIKV Seropositive Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 1 by Treatment Group for Baseline ZIKV Seronegative Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 2 by Treatment Group for Baseline ZIKV Seronegative Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 1 by Treatment Group for Baseline ZIKV Seropositive and DENV Seropositive Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 2 by Treatment Group for Baseline ZIKV Seropositive and DENV Seropositive Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 1 by Treatment Group for Baseline ZIKV Seropositive and DENV Seronegative Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 2 by Treatment Group for Baseline ZIKV Seropositive and DENV Seronegative Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 1 by Treatment Group for Baseline ZIKV Seronegative and DENV Seropositive Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 2 by Treatment Group for Baseline ZIKV Seronegative and DENV Seropositive Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 1 by Treatment Group for Baseline ZIKV Seronegative and DENV Seronegative Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Solicited Systemic Events Post Dose 2 by Treatment Group for Baseline ZIKV Seronegative and DENV Seronegative Participants
The following systemic solicited events were measured: feverishness, fatigue, malaise, myalgia, arthralgia, headache, nausea, vomiting, diarrhea, abdominal pain, rash, and fever. Participants who reported not having a symptom are listed as "None", while participants who did not complete their Memory Aid or could not remember whether they had a symptom are listed as "Not Reported". Severity is the maximum severity reported over all solicited symptoms post dosing for each participant.
Frequency and Severity of Unsolicited Adverse Events by Treatment Group for All Participants
Adverse events (AEs) are defined as any untoward medical occurrence regardless of its causal relationship to study treatment. Number of participants with an AE are summarized by MedDRA System Organ Class (SOC). If a condition was present at screening, it was not considered an AE unless the severity worsened.
Frequency and Severity of Unsolicited Adverse Events by Treatment Group for Baseline ZIKV Seropositive Participants
Adverse events (AEs) are defined as any untoward medical occurrence regardless of its causal relationship to study treatment. Number of participants with an AE are summarized by MedDRA System Organ Class (SOC). If a condition was present at screening, it was not considered an AE unless the severity worsened.
Frequency and Severity of Unsolicited Adverse Events by Treatment Group for Baseline ZIKV Seronegative Participants
Adverse events (AEs) are defined as any untoward medical occurrence regardless of its causal relationship to study treatment. Number of participants with an AE are summarized by MedDRA System Organ Class (SOC). If a condition was present at screening, it was not considered an AE unless the severity worsened.
Frequency and Severity of Unsolicited Adverse Events by Treatment Group for Baseline ZIKV Seropositive and DENV Seropositive Participants
Adverse events (AEs) are defined as any untoward medical occurrence regardless of its causal relationship to study treatment. Number of participants with an AE are summarized by MedDRA System Organ Class (SOC). If a condition was present at screening, it was not considered an AE unless the severity worsened.
Frequency and Severity of Unsolicited Adverse Events by Treatment Group for Baseline ZIKV Seropositive and DENV Seronegative Participants
Adverse events (AEs) are defined as any untoward medical occurrence regardless of its causal relationship to study treatment. Number of participants with an AE are summarized by MedDRA System Organ Class (SOC). Each participant was counted once per SOC. If a condition was present at screening, it was not considered an AE unless the severity worsened.
Frequency and Severity of Unsolicited Adverse Events by Treatment Group for Baseline ZIKV Seronegative and DENV Seropositive Participants
Adverse events (AEs) are defined as any untoward medical occurrence regardless of its causal relationship to study treatment. Number of participants with an AE are summarized by MedDRA System Organ Class (SOC). If a condition was present at screening, it was not considered an AE unless the severity worsened.
Frequency and Severity of Unsolicited Adverse Events by Treatment Group for Baseline ZIKV Seronegative and DENV Seronegative Participants
Adverse events (AEs) are defined as any untoward medical occurrence regardless of its causal relationship to study treatment. Number of participants with an AE are summarized by MedDRA System Organ Class (SOC). If a condition was present at screening, it was not considered an AE unless the severity worsened.
Frequency and Type of Serious Adverse Events (SAE) Considered Related to Study Vaccine for All Participants
SAEs included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation or a congenital anomaly/birth defect.
Duration of Serious Adverse Events (SAE) Considered Related to Study Vaccine for All Participants
SAEs included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation or a congenital anomaly/birth defect.
Frequency and Type of Adverse Events of Special Interest (AESI) Considered Related to Study Vaccine for All Participants
For this study Neurologic and Neuroinflammatory Disorders after the first vaccination were considered as Adverse Events of Special Interest (AESI).
Duration of Adverse Events of Special Interest (AESI) Considered Related to Study Vaccine for All Participants
For this study Neurologic and Neuroinflammatory Disorders after the first vaccination were considered as Adverse Events of Special Interest (AESI).
Frequency of New Onset Chronic Medical Conditions for All Participants
New onset chronic medical conditions (NOCMCs) were any new medical conditions reported from the first administration of study vaccine until the end of the study.
Comparison of Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for All Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for All Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seropositive Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seropositive Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seronegative Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seronegative Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seropositive and DENV Seropositive Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seropositive and DENV Seropositive Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency, Type, and Duration of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seropositive and DENV Seronegative Participants
The number of participants experiencing each adverse event and the median duration of adverse events are listed.
Comparison of the Frequency, Type, and Duration of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seropositive and DENV Seronegative Participants
The number of participants experiencing each adverse event and the median duration of adverse events are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seronegative and DENV Seropositive Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seronegative and DENV Seropositive Participants
The number of participants experiencing each adverse event will be listed
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seronegative and DENV Seronegative Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Frequency and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seronegative and DENV Seronegative Participants
The number of participants experiencing each adverse event are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for All Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for All Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seropositive Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seropositive Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seronegative Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seronegative Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seropositive and DENV Seropositive Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seropositive and DENV Seropositive Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seronegative and DENV Seropositive Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type Duration of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seronegative and DENV Seropositive Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 1 for Baseline ZIKV Seronegative and DENV Seronegative Participants
The median duration of adverse events are listed.
Comparison of the Duration and Type of Vaccine-related Grade 3 Local, Systemic, or Laboratory AE, and Grade 2 or Greater Local or Systemic Reactogenicity Post Dose 2 for Baseline ZIKV Seronegative and DENV Seronegative Participants
The median duration of adverse events are listed.
Comparison of Study Withdrawals and Discontinuation of Study Vaccination Due to Any Reason for All Participants
Comparisons of the number of participants who withdrew early and who discontinued treatment are presented.
Comparison of Study Withdrawals and Discontinuation of Study Vaccination Due to Any Reason for Baseline ZIKV Seropositive Participants
Comparisons of the number of participants who withdrew early and who discontinued treatment are presented.
Comparison of Study Withdrawals and Discontinuation of Study Vaccination Due to Any Reason for Baseline ZIKV Seronegative Participants
Comparisons of the number of participants who withdrew early and who discontinued treatment are presented.
Comparison of Study Withdrawals and Discontinuation of Study Vaccination Due to Any Reason for Baseline ZIKV Seropositive and DENV Seropositive Participants
Comparisons of the number of participants who withdrew early and who discontinued treatment are presented.
Comparison of Study Withdrawals and Discontinuation of Study Vaccination Due to Any Reason for Baseline ZIKV Seropositive and DENV Seronegative Participants
Comparisons of the number of participants who withdrew early and who discontinued treatment are presented.
Comparison of Study Withdrawals and Discontinuation of Study Vaccination Due to Any Reason for Baseline ZIKV Seronegative and DENV Seropositive Participants
Comparisons of the number of participants who withdrew early and who discontinued treatment are presented.
Comparison of Study Withdrawals and Discontinuation of Study Vaccination Due to Any Reason for Baseline ZIKV Seronegative and DENV Seronegative Participants
Comparisons of the number of participants who withdrew early and who discontinued treatment are presented.